Evidence map›Paper›PMID 22343313›Full record

ReviewNeuroscience letters2012

Combination therapies in the CNS: engineering the environment.

Dylan A McCreedy, Shelly E Sakiyama-Elbert

Open access · greenAbstract readReview
In one paragraph

Review in Neuroscience letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Cell transplantation to repair the injured spinal cord.International review of neurobiology · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. [Review of the regeneration mechanism of complete spinal cord injury].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2018
    Review
  12. Article
  13. Fibroblast growth factors in the management of spinal cord injury.Journal of cellular and molecular medicine · 2018
    Review
  14. Article
  15. Review
  16. Review
  17. Ibuprofen-loaded fibrous patches-taming inhibition at the spinal cord injury site.Journal of materials science. Materials in medicine · 2017
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Dylan A McCreedyDepartment of Biomedical Engineering, Washington University in St. Louis, 1 Brookings Dr. Box 1097, St. Louis, MO 63130, United States.
Shelly E Sakiyama-Elbert
Washington University in St. Louis · US

Funding

FIBRIN BASED SCAFFOLDS FOR SPINAL CORD INJURYR01NS051454 · NINDS · WASHINGTON UNIVERSITY · PI SAKIYAMA-ELBERT, SHELLY ELESE · 2005 to 2013
$2.4M
NINDS NIH HHS R01 NS051454
6 · The paper itself

Abstract

The inhibitory extracellular environment that develops in response to traumatic brain injury and spinal cord injury hinders axon growth thereby limiting restoration of function. Several strategies have been developed to engineer a more permissive central nervous system (CNS) environment to promote regeneration and functional recovery. The multi-faced inhibitory nature of the CNS lesion suggests that therapies used in combination may be more effective. In this mini-review we summarize the most recent attempts to engineer the CNS extracellular environment after injury using combinatorial strategies. The advantages and limits of various combination therapies utilizing neurotrophin delivery, cell transplantation, and biomaterial scaffolds are discussed. Treatments that reduce the inhibition by chondroitin sulfate proteoglycans, myelin-associated inhibitors, and other barriers to axon regeneration are also reviewed. Based on the current state of the field, future directions are suggested for research on combination therapies in the CNS.

Indexed as

Biocompatible MaterialsBrain InjuriesCell TransplantationCombined Modality TherapyHumansNeovascularization, PhysiologicNerve Growth FactorsNeuroprotective AgentsSpinal Cord InjuriesTissue ScaffoldsBiocompatible MaterialsNerve Growth FactorsNeuroprotective Agents

Identifiers

PMID22343313
PMCPMC3377780
OpenAlexW2081968410

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.